UPDATE: Leerink On Alexion Warns Of Near-Term Negative Impact On Stock But Says Given Regulatory Decision, Biosimilar Developer Of Eculizumab Would Not Be Able To Manufacture, Sell An Alternative Product In Brazil For At Least 2-3 Years